Fuzheng Huayu capsule as an adjuvant treatment for HBV‐related cirrhosis: A systematic review and meta‐analysis

摘要

>Fuzheng Huayu (FZHY) capsule, a formulated traditional Chinese medicine product with 6 Chinese herbs, is widely used for HBV‐related cirrhosis as an adjuvant treatment. However, the efficacy of FZHY capsule for HBV‐induced cirrhosis did not be comprehensively proved by systematic analysis. Our current analysis was aimed to assess the efficacy and safety of FZHY capsule by an evidence‐based method. Databases, including China National Knowledge Infrastructure, Wangfang, VIP medicine information system, Pubmed, Embase, and Cochrane Library, were searched, and the randomized controlled trials of FZHY capsule were used for the treatment of HBV‐associated liver cirrhosis. Meta‐analysis was performed by Review Manager 5.3. The efficacy rate, alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB), Procollagen III protein (PIIIP), hyaluronic acid (HA), laminin (LN), Collagen C Type IV (IV‐C), Child‐Pugh score, portal vein diameter, spleen thickness, HBeAg negative conversion rate, and HBV‐DNA negative conversion rate were systematically assessed. The Cochrane Risk of Bias tool was used to evaluate the methodological quality of eligible studies. Nineteen studies with 1,769 patients were included in the meta‐analysis. Compared to conventional treatment, FZHY capsule was effective by increasing the efficacy. FZHY capsule was more efficient in improving ALT, AST, TBIL, PIIIP, HA, LN, IV‐C, Child‐Pugh grading score, portal vein diameter, spleen thickness, and HBV‐DNA negative conversion rate with no serious adverse reactions. Nevertheless, a variety of well‐designed randomized controlled trials are needed to confirm these findings since small samples were applied in the previous studies.